Johnson & Johnson, through an affiliate, currently holds approximately 17.9 percent of the outstanding shares of Crucell. The companies said they expect that “Crucell’s strength in the manufacture, discovery and commercialization of vaccines would create a strong platform for Johnson & Johnson in the vaccine market.” Both companies “expect that Crucell, as Johnson & Johnson’s vaccine center, would retain its entrepreneurial culture that has fostered innovation and growth. http://www.jnj.com/connect/news/all/Johnson-and-Johnson-and-Crucell-in-advanced-negotiations-for-an-all-cash-public-offer Johnson & Johnson and Crucell announced that they are “in advanced negotiations for a potential public offer by Johnson & Johnson or an affiliate for all outstanding ordinary shares of Crucell not already held by Johnson & Johnson and its affiliates.